An interventional study of Paper-based questionnaire administration and Electronic questionnaire administration in Quality of Life, Breast Cancer and Prostate Cancer, sponsored by Masaryk Memorial Cancer Institute. Completed at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Masaryk Memorial Cancer Institute · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 177 studies in Breast Neoplasms with a site in Czechia — 21 open to participants now, 44 under way, 31 of them phase 3. Breast Neoplasms · Czechia.
Among the 177 studies in Breast Neoplasms with a site in Czechia, this one is the 115th largest by enrollment of the 161 interventional ones that give a count, is one of 6 that started in 2024, is one of 9 with no phase, and was the 177th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →21 of the 177 studies in Breast Neoplasms with a site in Czechia are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Czechia, United States, Argentina and 23 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Czechia, United States, Canada and 8 more countries
Ages 18+
Masaryk Memorial Cancer Institute · Sites in Czechia
Ages 20–55 · Women only · Healthy volunteers
Olema Pharmaceuticals, Inc. · Sites in Czechia, United States, Australia and 20 more countries
Ages 18+
BioNTech SE · Sites in Czechia, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
177 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 49 · Phase 3 103
First in 1996; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 228 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 500 across the 161 interventional studies, 200 across the 15 observational. Of the 131 that completed or were terminated, 98 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 177 have an industry lead sponsor. The 10 most frequent:
Masaryk Memorial Cancer Institute is the lead sponsor of 16 studies on the registry; 10 are open to participants now.
Masaryk Memorial Cancer Institute has 5 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Breast Neoplasms with a site in Czechia that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT06312176Phase 3Merck Sharp & Dohme LLCA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | 2027-07-11 |
Add all 12 to your calendar (.ics) → With an account.
Among the 177 studies in Breast Neoplasms with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized study is to evaluate the feasibility of electronic questionnaires for assessing health-related quality of life in adults with breast or prostate cancer undergoing radiotherapy.
The main questions are:
Participants were randomly assigned to one of two groups:
Both groups were asked to complete the same quality-of-life questionnaires at three time points: during radiotherapy planning, on the first day of radiotherapy, and on the last day of radiotherapy.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received printed questionnaires provided by healthcare staff.
Other: Paper-based questionnaire administration
Participants received questionnaires online and could complete them using a computer, tablet, or smartphone.
Other: Electronic questionnaire administration
Administration of printed EORTC QLQ-C30 and disease-specific HRQoL questionnaires (QLQ-BR45 or QLQ-PR25) at three predefined time points (T0, T1, and T2). Questionnaires are distributed by healthcare staff during scheduled visits, and completed responses are subsequently entered into the electronic study database.
Administration of EORTC QLQ-C30 and disease-specific HRQoL questionnaires (QLQ-BR45 or QLQ-PR25) through a secure web-based platform at three predefined time points (T0, T1, and T2). Participants can complete questionnaires remotely using a computer, tablet, or smartphone. Automated reminders are sent by email and/or text message, with telephone follow-up if necessary.
Questionnaire completion rate
Proportion of participants with an available completed HRQoL assessment at each of the three scheduled time points (T0, T1, and T2), evaluated separately for electronic and paper-based questionnaire administration.
Time frame: Baseline (T0), start of radiotherapy (T1), and end of radiotherapy (T2), approximately 6-8 weeks.
Availability of paired baseline and final HRQoL assessments
Proportion of participants with available HRQoL assessments at both baseline (T0) and the last day of radiotherapy (T2), evaluated separately for electronic and paper-based questionnaire administration.
Time frame: From baseline (T0) to the end of radiotherapy (T2), approximately 6-8 weeks.
Availability of complete longitudinal HRQoL assessments
Proportion of participants with available HRQoL assessments at all three scheduled time points (T0, T1, and T2), evaluated separately for electronic and paper-based questionnaire administration.
Time frame: From baseline (T0) to the end of radiotherapy (T2), approximately 6-8 weeks.
Health-related quality of life
Health-related quality of life is assessed using the EORTC QLQ-C30 and disease-specific QLQ-BR45 (breast cancer) or QLQ-PR25 (prostate cancer) questionnaires. Scale scores range from 0 to 100, with higher scores indicating better functioning on functional and global health status scales and greater symptom burden on symptom scales. Results are evaluated separately for electronic and paper-based questionnaire administration.
Time frame: Baseline (T0), start of radiotherapy (T1), and end of radiotherapy (T2), approximately 6-8 weeks.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Jan 2025, 12 months.
Of 2,664 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 12 months is below that.
Counting every sponsor, half of 2,774 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Masaryk Memorial Cancer Institute